Skip to main content

Table 1 EZH2 gain in BRAF V600E mutated melanoma

From: Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy

Melanoma subtypes

Number of cases

Number of cases with EZH2 gain (%)

Acral melanoma

41

9 (22.5)

Mucosal melanoma

18

7 (17.5)

CSD

36

9 (22.5)

Non-CSD

39

13 (32.5)

Total

138

40 (29.0)

P value

 

0.346

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us